New York, August 14, 2014 -- Moody's Investors Service commented that the proposed amendment and consent related to the term loan of Auxilium Pharmaceuticals, Inc. will reduce financial flexibility but has no effect on Auxilium's existing ratings or outlook. The unaffected ratings include Auxilium's B3 Corporate Family Rating, Ba3 senior secured term loan rating, and SGL-4 Speculative Grade Liquidity rating. The rating outlook is negative.
Vollständigen Artikel bei Moodys lesen
Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.